It’s a sobering statistic: 1 in 8 women in the United States will be diagnosed with breast cancer during her lifetime.1 ...
Several major drugmakers have restricted commercially insured patients from their patient assistance programs, leaving ...
Dr. Maxwell Lloyd discusses the long-term management of patients with HR-positive, HER2-negative breast cancer who have received Orserdu treatment.
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — ...
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
The American Cancer Society is asking North Dakota State lawmakers to pass legislation that would require insurance companies to cover diagnostic testing for people who need it when doctors find ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback